ArticleBreast cancer research and treatment2022

Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study.

Xinguang Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.